Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AROA BIOSURGERY LIMITED Director's Dealing 2023

Sep 6, 2023

64426_rns_2023-09-06_04d1cc46-3343-4938-a13e-87c98cc0bfd4.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Aroa Biosurgery Limited ARBN 638 867 473

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director James McLean
Date of last notice 31 March 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
N/A
Date of change 6 September 2023
No. of securities held prior to change Direct
2,674,708 Fully Paid Ordinary Share
102,400 Fully Paid Ordinary Share, to be
held in escrow until 13 April 2023
102,400
Options exercisable at $0.75
expiring 23 July 2025
258,929 Options exercisable at $1.083
expiring 29 February 2028
Class (a)
Fully Paid Ordinary Shares
(b)
Options exercisable at $0.75 expiring 23
July 2025
Number acquired (a)
50,000
(b)
Nil
Number disposed (a) Nil
(b) 50,000
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$37,500
  • See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change

Nature of change

Direct 2,827,108 Fully Paid Ordinary Share 52,400 Options exercisable at $0.75 expiring 23 July 2025 258,929 Options exercisable at $1.083 expiring 29 February 2028 Exercise of Options

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract -
Nature of interest -
Name of registered holder
(if issued securities)
-
Date of change -
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in
relation to which the interest has changed
-
Interest acquired -
Interest disposed -
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
-
Interest after change -

Part 3 –[+] Closed period

Were the interests in the securities No or contracts detailed above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011